Accuray claims that the CyberKnife M6 offers the widest range of motion and highest-precision conformal delivery available and enables patients to lie comfortably and breathe freely at the time of receiving precise, high dose radiation therapy in a relatively short number of treatments.

The CyberKnife technology allows clinicians to precisely maximize dose, minimize side effects and maximize patient comfort. The device automatically adjusts the beam for target movement and enables reduced margins while minimizing radiation exposure to healthy tissue and critical organs.

According to Accuray, patients treated with CyberKnife System will not experience the discomfort of breath-holding, abdominal compression, breathing apparatus, or metal head-frames typically associated with other radiation therapy devices.

Accuray president and CEO Joshua H Levine noted that this marks a key milestone in the company’s strategic growth plan for the market in Japan.

"We are very pleased to provide the latest CyberKnife technology to our customers and their patients in Japan.

"The CyberKnife M6 Series offers advantages of increased clinical flexibility, greatly reduced treatment times and ease of use for clinicians, while providing patients the most precise tumor treatment available," Levine added.

Accuray will market the CyberKnife M6 system in Japan as the CyberKnife M6 Series.

Accuray has obtained Shonin approval in July 2010 for its CyberKnife G4 System for use in Japan in the treatment of tumors in the body, inclusive of the head and neck. The company obtained Shonin approval in 2012 for the CyberKnife VSI system for robotic radiosurgery.